Mast Therapeutics, Inc. (MSTX)

[Ecomike]

New 8-K (prelude to buy out at $16 someday?):

On June 28, 2011, the Audit Committee of the Board of Directors of ADVENTRX Pharmaceuticals, Inc. (the "Company") engaged PricewaterhouseCoopers LLP, or PwC, as its independent registered public accounting firm. During the years ended December 31, 2010 and 2009 and through June 28, 2011, neither the Company nor anyone on its behalf consulted with PwC regarding (a) the application of accounting principles to a specified transaction, either completed or proposed, or the type of audit opinion that might be rendered on the Company's consolidated financial statements, and neither a written report nor oral advice was provided to the Company that PwC concluded was an important factor considered by the Company in reaching a decision as to the accounting, auditing or financial reporting issue; or (b) any matter that was either the subject of a disagreement (as defined in Item 304(a)(1)(iv) of Regulation S-K and the related instructions to Item 304 of Regulation S-K) or a reportable event (as described in Item 304(a)(1)(v) of Regulation S-K).